Novo Nordisk halts CLARION-CKD trial, recognizes DKK 5.7B loss for ocedurenone.

Novo Nordisk has stopped its CLARION-CKD phase 3 trial investigating ocedurenone in patients with uncontrolled hypertension and advanced chronic kidney disease. The trial failed to meet its primary endpoint of change in systolic blood pressure. Consequently, Novo Nordisk will recognize an impairment loss of around DKK 5.7 billion related to ocedurenone in the second quarter of 2024.